The INCA trial: a multicenter, randomized, phase II, open-label clinical trial to evaluate the combination therapy with Ipilimumab plus Nivolumab versus Chemotherapy (Pemetrexate-Cisplatin) in patients with Advanced non-squamous NSCLC naive to treatment. (2018). Principles and Practice of Clinical Research, 4(1), 6-13. https://journal.ppcr.org/index.php/ppcrjournal/article/view/62